| Source: |
| Type: type of cell death |
| Situation in which a cell actively pursues a course toward death upon receiving certain stimuli. Cancer is one of the scenarios where too little apoptosis occurs, resulting in malignant cells that will not die. |
| 1112- | FA, | Ferulic acid exerts antitumor activity and inhibits metastasis in breast cancer cells by regulating epithelial to mesenchymal transition |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | BC, | NA |
| 2494- | Fenb, | Oral Fenbendazole for Cancer Therapy in Humans and Animals |
| - | Review, | Var, | NA |
| 2851- | FIS, | Apoptosis-induction-in-breast-cancer">Apoptosis induction in breast cancer cell lines by the dietary flavonoid fisetin |
| - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | SkBr3 | - | in-vitro, | Nor, | NA |
| 2853- | FIS, | Fisetin Inhibits Cell Proliferation and Induces Apoptosis via JAK/STAT3 Signaling Pathways in Human Thyroid TPC 1 Cancer Cells |
| - | in-vitro, | Thyroid, | TPC-1 |
| - | in-vitro, | RCC, | Caki-1 |
| 2857- | FIS, | A review on the chemotherapeutic potential of fisetin: In vitro evidences |
| - | Review, | Var, | NA |
| 2844- | FIS, | Fisetin, a dietary flavonoid induces apoptosis via modulating the MAPK and PI3K/Akt signalling pathways in human osteosarcoma (U-2 OS) cells |
| - | in-vitro, | OS, | U2OS |
| 2826- | FIS, | Fisetin induces apoptosis in breast cancer MDA-MB-453 cells through degradation of HER2/neu and via the PI3K/Akt pathway |
| - | in-vitro, | BC, | MDA-MB-453 |
| 2829- | FIS, | Fisetin: An anticancer perspective |
| - | Review, | Var, | NA |
| 2839- | FIS, | Dietary flavonoid fisetin for cancer prevention and treatment |
| - | Review, | Var, | NA |
| 2841- | FIS, | Fisetin, an Anti-Inflammatory Agent, Overcomes Radioresistance by Activating the PERK-ATF4-CHOP Axis in Liver Cancer |
| - | in-vitro, | Nor, | RAW264.7 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | Hep3B | - | in-vitro, | Liver, | HUH7 |
| - | in-vitro, | Oral, | NA |
| 4028- | FulvicA, | Mineral pitch induces apoptosis and inhibits proliferation via modulating reactive oxygen species in hepatic cancer cells |
| - | in-vitro, | Liver, | HUH7 |
| 1300- | GA, | PacT, | carbop, | Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line |
| - | in-vitro, | BC, | MCF-7 |
| 935- | Gallo, | Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 934- | Gallo, | Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase |
| - | Analysis, | NA, | NA |
| 5205- | Gallo, | Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells |
| - | in-vitro, | Endo, | ISH |
| 5152- | GamB, | Gambogic Acid as a Candidate for Cancer Therapy: A Review |
| - | Review, | Var, | NA |
| 5149- | GamB, | Gambogic acid induces mitochondria-dependent apoptosis by modulation of Bcl-2 and Bax in mantle cell lymphoma JeKo-1 cells |
| - | in-vitro, | lymphoma, | JeKo-1 |
| 5150- | GamB, | Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-κB signaling pathway |
| - | in-vitro, | CLL, | KBM-5 | - | in-vitro, | Nor, | HEK293 |
| 5151- | GamB, | Gambogic acid affects ESCC progression through regulation of PI3K/AKT/mTOR signal pathway |
| - | in-vitro, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | KYSE450 |
| 1954- | GamB, | Gambogic acid induces apoptosis in hepatocellular carcinoma SMMC-7721 cells by targeting cytosolic thioredoxin reductase |
| - | in-vitro, | HCC, | SMMC-7721 cell |
| 1955- | GamB, | Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 |
| 1956- | GamB, | Gambogic Acid Inhibits Malignant Melanoma Cell Proliferation Through Mitochondrial p66shc/ROS-p53/Bax-Mediated Apoptosis |
| - | in-vitro, | Melanoma, | A375 |
| 1957- | GamB, | Nanoscale Features of Gambogic Acid Induced ROS-Dependent Apoptosis in Esophageal Cancer Cells Imaged by Atomic Force Microscopy |
| - | in-vitro, | ESCC, | EC9706 |
| 1961- | GamB, | Effects of gambogic acid on the activation of caspase-3 and downregulation of SIRT1 in RPMI-8226 multiple myeloma cells via the accumulation of ROS |
| - | in-vitro, | Melanoma, | RPMI-8226 |
| 1969- | GamB, | Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 1973- | GamB, | Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain |
| - | in-vitro, | Liver, | SMMC-7721 cell |
| 810- | GAR, | GEM, | Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures |
| - | in-vitro, | PC, | NA |
| 808- | GAR, | CUR, | Synergistic effect of garcinol and curcumin on antiproliferative and apoptotic activity in pancreatic cancer cells |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | PC, | PANC1 |
| 807- | GAR, | Garcinol inhibits cell proliferation and promotes apoptosis in pancreatic adenocarcinoma cells |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Bxpc-3 |
| 806- | GAR, | Garcinol exerts anti-cancer effect in human cervical cancer cells through upregulation of T-cadherin |
| - | vitro+vivo, | Pca, | HeLa | - | vitro+vivo, | Cerv, | SiHa |
| 802- | GAR, | Garcinol acts as an antineoplastic agent in human gastric cancer by inhibiting the PI3K/AKT signaling pathway |
| - | in-vitro, | GC, | HGC27 |
| 801- | GAR, | Cisplatin, | Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers |
| - | in-vivo, | HNSCC, | NA |
| 799- | GAR, | Apoptosis-inducing effect of garcinol is mediated by NF-kappaB signaling in breast cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | NMSC, | MCF10 |
| 798- | GAR, | Garcinol, an acetyltransferase inhibitor, suppresses proliferation of breast cancer cell line MCF-7 promoted by 17β-estradiol |
| - | in-vitro, | BC, | MCF-7 |
| 814- | GAR, | PacT, | Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA2 and NF-κB/Twist1 signaling pathways in a mouse 4T1 breast tumor model |
| - | in-vivo, | BC, | NA |
| 817- | GAR, | Garcinol inhibits esophageal cancer metastasis by suppressing the p300 and TGF-β1 signaling pathways |
| - | vitro+vivo, | SCC, | KYSE150 | - | vitro+vivo, | SCC, | KYSE450 |
| 818- | GAR, | GB, | Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs |
| - | in-vitro, | Lung, | A549 |
| 820- | GAR, | Garcinol in gastrointestinal cancer prevention: recent advances and future prospects |
| - | Review, | NA, | NA |
| 825- | GAR, | Garcinol-induced apoptosis in prostate and pancreatic cancer cells is mediated by NF- kappaB signaling |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | Bxpc-3 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | C4-2B |
| 796- | GAR, | Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression |
| - | vitro+vivo, | Pca, | HeLa |
| 831- | GAR, | CUR, | Induction of apoptosis by garcinol and curcumin through cytochrome c release and activation of caspases in human leukemia HL-60 cells |
| - | in-vitro, | AML, | HL-60 |
| 830- | GAR, | Garcinol modulates tyrosine phosphorylation of FAK and subsequently induces apoptosis through down-regulation of Src, ERK, and Akt survival signaling in human colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 793- | GAR, | Garcinol inhibits tumour cell proliferation, angiogenesis, cell cycle progression and induces apoptosis via NF-κB inhibition in oral cancer |
| - | in-vitro, | SCC, | SCC9 | - | in-vitro, | SCC, | SCC4 | - | in-vitro, | SCC, | SCC25 |
| 1189- | Gb, | New insight into the mechanisms of Ginkgo biloba leaves in the treatment of cancer |
| - | Review, | NA, | NA |
| 1187- | Gb, | Ginkgolic Acid C 17:1, Derived from Ginkgo biloba Leaves, Suppresses Constitutive and Inducible STAT3 Activation through Induction of PTEN and SHP-1 Tyrosine Phosphatase |
| - | in-vitro, | Melanoma, | U251 | - | in-vitro, | Melanoma, | MM.1S |
| 1186- | Gb, | Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis |
| - | in-vitro, | PC, | NA | - | in-vitro, | Nor, | HUVECs | - | in-vivo, | PC, | NA |
| 3723- | Gb, | Can We Use Ginkgo biloba Extract to Treat Alzheimer’s Disease? Lessons from Preclinical and Clinical Studies |
| - | Review, | AD, | NA |
| 28- | GEN, | Genistein decreases the breast cancer stem-like cell population through Hedgehog pathway |
| - | in-vivo, | BC, | MCF-7 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:14 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid